PMGC Holdings’ Northstrive Biosciences Announces Results From Phase III Of AI-Driven Drug Discovery Program With Strategic Partner Yuva Bios

Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development. NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB ) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences"). Phase III of the parties’ drug discovery program ("Phase III") was designed to biologically validate a focused set of small-molecule candidates sele...